StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Axis Securities

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byAxis SecuritiesHorizon: NA (inferred 1 year)12 Oct 2026via Institutional / Brokerage Research

Entry₹1,969.7Inferred
Target₹2,315
Total upside +17.53%
Stop lossNot given
CMP₹1,93812h ago
Active-1.61%+19.45%upside left 12 mo left
Follow Axis Securities for new calls(71% target hit, 807 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 2 other Long-term calls on LALPATHLABSee 133 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Oct, 4:32 am IST
18 supporting4 neutral0 opposing
Supports the BUY call (18)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·14 Oct · today

Dr. Lal PathLabs Ltd announces the completion of its acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, through its wholly-owned subsidiary DLPL Dubai. Sunshine Healthcare Limited is n

BSE · Company Update·26 Sept · 3w ago

(opens in new tab)

2 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·25 Sept · 3w ago

Dr. Lal Path Labs Ltd. approved the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. SN Genelab will become a subsidiary.

NSE · Outcome of Board Meeting·24 Sept · 3w ago

(opens in new tab)

Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. This acquisition aims to strengt

BSE · Company Update·24 Sept · 3w ago

(opens in new tab)
Neutral / worth noting (4)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 20 days

(opens in new tab)

Dr. Lal PathLabs' subsidiary, PathLabs Unifiers Private Limited, has acquired the remaining 30% stake in Centrapath Labs Private Limited, making it a wholly owned subsidiary.

BSE · Company Update·13 Oct · yesterday

(opens in new tab)

Dr. Lal PathLabs invested up to INR 30.3 crores in its wholly owned subsidiary, PathLabs Unifiers Private Limited, to fund the acquisition of the remaining 30% stake in CentraPath Labs Private Limited

BSE · Company Update·12 Oct · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Axis Securities

Every call and its outcome